197 related articles for article (PubMed ID: 19557804)
21. Characterization of a novel D2-like dopamine receptor with a truncated splice variant and a D1-like dopamine receptor unique to invertebrates from Caenorhabditis elegans.
Sugiura M; Fuke S; Suo S; Sasagawa N; Van Tol HH; Ishiura S
J Neurochem; 2005 Aug; 94(4):1146-57. PubMed ID: 16001968
[TBL] [Abstract][Full Text] [Related]
22. Phenylpiperazinylmethylheterocycle derivatives: synthesis and dopamine receptor binding profiles.
Abadi AH
Arch Pharm (Weinheim); 2004 Jul; 337(7):383-90. PubMed ID: 15237388
[TBL] [Abstract][Full Text] [Related]
23. Dopaminergic drugs in development for Parkinson's disease.
Korczyn AD
Adv Neurol; 2003; 91():267-71. PubMed ID: 12442685
[No Abstract] [Full Text] [Related]
24. Expression of D1 but not D2 dopamine receptors in striatal neurons producing neurokinin B in rats.
Sonomura T; Nakamura K; Furuta T; Hioki H; Nishi A; Yamanaka A; Uemura M; Kaneko T
Eur J Neurosci; 2007 Dec; 26(11):3093-103. PubMed ID: 18028111
[TBL] [Abstract][Full Text] [Related]
25. [Effects of activation and blockade of dopamine receptors on extinction of passive avoidance response in mice with depressive-like state].
Dubrovina NI; Zinov'eva DV
Zh Vyssh Nerv Deiat Im I P Pavlova; 2008; 58(5):605-10. PubMed ID: 19004320
[TBL] [Abstract][Full Text] [Related]
26. Chemical synthesis, microbial transformation and biological evaluation of tetrahydroprotoberberines as dopamine D1/D2 receptor ligands.
Ge H; Zhang Y; Yang Z; Qiang K; Chen C; Sun L; Chen M; Zhang J
Bioorg Med Chem; 2019 May; 27(10):2100-2111. PubMed ID: 30981605
[TBL] [Abstract][Full Text] [Related]
27. D2 receptor stimulation, but not D1, restores striatal equilibrium in a rat model of Parkinsonism.
Ballion B; Frenois F; Zold CL; Chetrit J; Murer MG; Gonon F
Neurobiol Dis; 2009 Sep; 35(3):376-84. PubMed ID: 19501163
[TBL] [Abstract][Full Text] [Related]
28. The dopaminergic stabilizer ASP2314/ACR16 selectively interacts with D2(High) receptors.
Seeman P; Tokita K; Matsumoto M; Matsuo A; Sasamata M; Miyata K
Synapse; 2009 Oct; 63(10):930-4. PubMed ID: 19588469
[TBL] [Abstract][Full Text] [Related]
29. Selective pharmacophore models of dopamine D(1) and D(2) full agonists based on extended pharmacophore features.
Malo M; Brive L; Luthman K; Svensson P
ChemMedChem; 2010 Feb; 5(2):232-46. PubMed ID: 20077461
[TBL] [Abstract][Full Text] [Related]
30. Dopaminergic modulation of afferent synaptic transmission in the semicircular canals of frogs.
Andrianov GN; Ryzhova IV; Tobias TV
Neurosignals; 2009; 17(3):222-8. PubMed ID: 19546593
[TBL] [Abstract][Full Text] [Related]
31. CoMFA and CoMSIA investigations revealing novel insights into the binding modes of dopamine D3 receptor agonists.
Boeckler F; Ohnmacht U; Lehmann T; Utz W; Hübner H; Gmeiner P
J Med Chem; 2005 Apr; 48(7):2493-508. PubMed ID: 15801839
[TBL] [Abstract][Full Text] [Related]
32. Role of the extracellular amino terminus and first membrane-spanning helix of dopamine D1 and D5 receptors in shaping ligand selectivity and efficacy.
D'Aoust JP; Tiberi M
Cell Signal; 2010 Jan; 22(1):106-16. PubMed ID: 19786093
[TBL] [Abstract][Full Text] [Related]
33. Dopamine/serotonin receptor ligands. 10: SAR Studies on azecine-type dopamine receptor ligands by functional screening at human cloned D1, D2L, and D5 receptors with a microplate reader based calcium assay lead to a novel potent D1/D5 selective antagonist.
Hoefgen B; Decker M; Mohr P; Schramm AM; Rostom SA; El-Subbagh H; Schweikert PM; Rudolf DR; Kassack MU; Lehmann J
J Med Chem; 2006 Jan; 49(2):760-9. PubMed ID: 16420061
[TBL] [Abstract][Full Text] [Related]
34. Dopamine/serotonin receptor ligands. Part 17: a cross-target SAR approach: affinities of azecine-styled ligands for 5-HT(2A) versus D1 and D2 receptors.
Enzensperger C; Görnemann T; Pertz HH; Lehmann J
Bioorg Med Chem Lett; 2008 Jul; 18(13):3809-13. PubMed ID: 18534847
[TBL] [Abstract][Full Text] [Related]
35. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
Darmopil S; Martín AB; De Diego IR; Ares S; Moratalla R
Biol Psychiatry; 2009 Sep; 66(6):603-13. PubMed ID: 19520364
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and pharmacological evaluation of thiazole and isothiazole derived apomorphines.
Sipos A; Mueller FK; Lehmann J; Berényi S; Antus S
Arch Pharm (Weinheim); 2009 Oct; 342(10):557-68. PubMed ID: 19714675
[TBL] [Abstract][Full Text] [Related]
37. Dopamine receptor ligands. Part 18: (1) modification of the structural skeleton of indolobenzazecine-type dopamine receptor antagonists.
Robaa D; Enzensperger C; Abul Azm Sel D; El Khawass el S; El Sayed O; Lehmann J
J Med Chem; 2010 Mar; 53(6):2646-50. PubMed ID: 20180564
[TBL] [Abstract][Full Text] [Related]
38. Biochemical identification of the dopamine D2 receptor domains interacting with the adenosine A2A receptor.
Torvinen M; Kozell LB; Neve KA; Agnati LF; Fuxe K
J Mol Neurosci; 2004; 24(2):173-80. PubMed ID: 15456930
[TBL] [Abstract][Full Text] [Related]
39. Development of a bivalent dopamine D₂ receptor agonist.
Kühhorn J; Götz A; Hübner H; Thompson D; Whistler J; Gmeiner P
J Med Chem; 2011 Nov; 54(22):7911-9. PubMed ID: 21999579
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines.
Sipos A; Csutorás C; Berényi S; Uustare A; Rinken A
Bioorg Med Chem; 2008 Apr; 16(8):4563-8. PubMed ID: 18313931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
